

**AMED FY2026 “Translational Research Project” Grant Awarded to a Joint Research and Development Project Conducted by Yamaguchi University and Kyushu University, Collaborative Partners of Noile-Immune
Noile-Immune participates as an industry partner**

Noile-Immune Biotech, Inc. (hereinafter “the Company”) hereby announces that a research and development project (the “Project”) on CAR-T cell therapy for glioblastoma, jointly proposed by its collaborative partners, Yamaguchi University and Kyushu University, has been selected for funding under the FY2026 “Translational Research Program” of the Japan Agency for Medical Research and Development (AMED). The Company will participate in this Project as an industry partner responsible for commercialization.


Project Title	Study of First-in-Human Investigator-Initiated Phase I Clinical Trial of Anti-EGFRvIII CAR-T Cell Therapy with Next-Generation Immune-Enhancement Technology for Glioblastoma
Grant Period	May 2026 (planned) – FY2030 (up to 5 fiscal years)
Principal Investigator	Koji Yoshimoto, M.D., Ph.D. (Professor, Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University)
Co-Investigators	Koji Tamada, MD, Ph.D. (Professor, Department of Immunology, Yamaguchi University Graduate School of Medicine), et al.
Industry Partner	Noile-Immune Biotech Inc.
AMED Website	https://www.amed.go.jp/koubo/03007/01/C_00001.html (Japanese version URL)

Under this award, the Project is expected to receive a grant of up to JPY 410 million over a maximum period of five years (subject to stage-gate evaluation). The Project will advance the development of the Company’s pipeline candidate NIB104, targeting glioblastoma, and an investigator-initiated Phase I clinical trial led by the Principal Investigator is planned to be conducted at Kyushu University Hospital. Through the execution of this Project, further strengthening of the Company’s pipeline and acceleration of its business development are anticipated.

Glioblastoma is the most common and most aggressive form of malignant primary brain tumor. It is associated with poor prognosis, high recurrence rates even after standard treatment, and limited effective therapeutic options, representing a significant unmet medical need that urgently requires innovative treatment approaches. NIB104 targets EGFRvIII expressed in glioblastoma and is a next-generation CAR-T cell therapy, “Swift PRIME CAR-T,” which combines the Company’s proprietary PRIME technology with its Swift manufacturing platform (short-term culture method). It is characterized by superior tumor trafficking, expansion, persistence, and high manufacturing efficiency (see figure in the next page).

The impact of this matter on the Company’s financial results for the fiscal year ending December 2026 is currently under evaluation. Should any matters requiring disclosure arise, the Company will promptly provide an update.

Key Features of Next-Generation Swift PRIME CAR-T Cells



【Noile-Immune Biotech Inc.】

Noile-Immune Biotech Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.

For more information, please visit <https://www.noile-immune.com/en.html>.

Contact for inquiries or additional information

2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan

Noile-Immune Biotech Inc.

pr@noile-immune.com